Skip to main content

Advertisement

SpringerLink
Log in

Botulinum toxin for the treatment of musculoskeletal pain and spasm

  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

The impressive pain relief experienced by sufferers of dystonia and spasticity from intramuscular injections of botulinum toxin suggested that patients with other chronic, musculoskeletal pain conditions also may benefit. However, there have been relatively few placebo-controlled studies of botulinum toxin in such non-neurologic conditions as myofascial pain syndrome, chronic neck and low back pain, and fibromyalgia; the results of these studies have not been impressive. One explanation for the lack of positive findings may be the lack of clinically evident muscle spasms (overactivity), despite the presence of muscle tenderness, tightness, or trigger points. Clinical observations of pain relief from injections of botulinum toxin for dystonia and spasticity and its apparent efficacy in treating migraine suggest an anti-nociceptive action independent of its neuromuscular junction-blocking action. Evidence from animal experiments supports this notion, and other data provide plausible physiologic mechanisms in the periphery and central nervous systems. These involve modulation of the activity of the neurotransmitters glutamate, substance P, calcitonin gene-related peptide, enkephalins, and others. However, even if botulinum toxin is firmly established as an analgesic, there is insufficient clinical evidence of its efficacy in treating non-neurologic, chronic, musculoskeletal pain conditions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Aoki R: Pharmacology and immunology of botulinum toxin serotypes. J Neurol 2001, 248(suppl 1):3–10.

    Article  PubMed  CAS  Google Scholar 

  2. Jankovic J, Schwartz K: Botulinum toxin injections for cervical dystonia. Neurology 1990, 40:277–280.

    Article  PubMed  CAS  Google Scholar 

  3. Chadlkiadaki A, Rohr UP, Hefter H: Early pain reduction in the treatment of spasticity after a single injection of botulinum A toxin. Deutsch Med Wochenschr 2001, 126:1361–1364.

    Article  Google Scholar 

  4. Giladi N: The mechanism of action of botulinum toxin type A in focal dystonia is most probably through its dual effect on efferent (motor) and afferent pathways at the injected site. J Neurol Sci 1997, 152:132–135.

    Article  PubMed  CAS  Google Scholar 

  5. Guyer BM: Mechanism of botulinum toxin in the relief of chronic pain. Curr Rev Pain 1999, 3:427–431.

    PubMed  Google Scholar 

  6. Borodic GE, Acquadro M, Johnson EA: Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Expert Opin Investig Drugs 2001, 10:1531–1544.

    Article  PubMed  CAS  Google Scholar 

  7. Silberstein S, Mathew N, Saper J, Jenkins S: Botulinum toxin type A as a migraine preventive treatment: for the Botox Migraine Clinical Research Group. Headache 2000, 40:445–450.

    Article  PubMed  CAS  Google Scholar 

  8. Ceballos-Baumann AO: Evidence-based medicine in botulinum toxin therapy for cervical dystonia. J Neurol 2001, 248 (suppl 1):14–20.

    Article  PubMed  Google Scholar 

  9. Reichel G: Botulinum toxin for treatment of spasticity in adults. J Neurol 2001, 248 (suppl 1):25–27.

    Article  PubMed  CAS  Google Scholar 

  10. Freund B, Schwartz M, Symington JM: Botulinum toxin: new treatment for temporomandibular disorders. Br J Oral Maxillofac Surg 2000, 38:466–471.

    Article  PubMed  CAS  Google Scholar 

  11. Fernandez Lopez F, Conde Freire R, Rios Rios A, et al.: Botulinum toxin for the treatment of anal fissure. Dig Surg 1999, 16:515–518.

    Article  Google Scholar 

  12. Hoogerwerf WA, Pasricha PJ: Botulinum toxin for spastic gastrointestinal disorders. Baillieres Best Pract Res Clin Gastroenterol 1999, 13:131–143.

    Article  PubMed  CAS  Google Scholar 

  13. Gobel H, Heinze A, Heinze-Kuhn K, Jost WH: Evidence-based medicine: botulinum toxin A in migraine and tension-type headache. J Neurol 2001, 248 (suppl 1):34–38.

    Article  PubMed  CAS  Google Scholar 

  14. Foster L, Clapp L, Erickson M, Jabbari B: Botulinum toxin A and chronic low back pain: a randomized, double-blind study. Neurology 2001, 56:1290–1293. This is the only controlled study of botulinum toxin in the treatment of low back pain. Patients receiving botulinum toxin-A obtained greater pain relief and improved function compared with the placebo group. Although only 31 patients were observed, the results are encouraging.

    PubMed  CAS  Google Scholar 

  15. Miller DJ: Comparison of electromyographic activity in the lumbar paraspinal muscles of subjects with and without chronic low back pain. Phys Ther 1985, 65:1347–1354.

    PubMed  CAS  Google Scholar 

  16. Nouwen A, Bush C: The relationship between paraspinal EMG and low back pain. Pain 1984, 20:109–123.

    Article  PubMed  CAS  Google Scholar 

  17. Wheeler AH, Goolkasian P: Open-label assessment of botulinum toxin A for pain treatment in a private outpatient setting. J Musculoskeletal Pain 2001, 9:67–82.

    Article  Google Scholar 

  18. Freund BJ, Schwartz M: Treatment of whiplash associated neck pain [corrected] with botulinum toxin-A: a pilot study. J Rheumatol 2000, 27:481–484.

    PubMed  CAS  Google Scholar 

  19. Wheeler AH, Goolkasian P, Gretz SS: Botulinum toxin A for the treatment of chronic neck pain. Pain 2001, 94:255–260. A study including 50 patients that showed no benefit of botulinum toxin type A injections.

    Article  PubMed  CAS  Google Scholar 

  20. Borg-Stein J, Simons DG: Myofascial pain. Arch Phys Med Rehabil 2002, 83(suppl 1):S40-S47. An excellent summary of myofascial pain syndrome, with detailed discussion of the pathophysiology.

    Article  PubMed  Google Scholar 

  21. Cheshire WP, Abashian SW, Mann JD: Botulinum toxin in the treatment of myofascial pain syndrome. Pain 1994, 59:65–69.

    Article  PubMed  CAS  Google Scholar 

  22. Wheeler AH, Goolkasian P, Gretz SS: A randomized, doubleblind, prospective pilot study of botulinum toxin injection for refractory, unilateral, cervicothoracic, paraspinal, myofascial pain syndrome. Spine 1998, 23:1662–1666.

    Article  PubMed  CAS  Google Scholar 

  23. Porta M: A comparative trial of botulinum toxin type A and methylprednisolone for the treatment of myofascial pain syndrome and pain from chronic muscle spasm. Pain 2000, 85:101–105.

    Article  PubMed  CAS  Google Scholar 

  24. Paulson GW, Gill W: Botulinum toxin is unsatisfactory therapy for fibromyalgia. Mov Disord 1996, 11:459.

    Article  PubMed  CAS  Google Scholar 

  25. Asherson RA, Pascoe LP: The use of botulinum toxin-A in the treatment of patients with fibromyalgia. J Rheumatol 2001, 28:1740. A trial of fibromyalgia, but trigger points were injected. This trial involved open-label injections of botulinum toxin type A, often in multiple sessions. All 16 patients reportedly responded well, with benefit lasting for 16 weeks.

    PubMed  CAS  Google Scholar 

  26. Morre HH, Keizer SB, van Os JJ: Treatment of chronic tennis elbow with botulinum toxin. Lancet 1997, 349:1746.

    Article  PubMed  CAS  Google Scholar 

  27. Tsui JK, Bhatt M, Calne S, Calne DB: Botulinum toxin in the treatment of writer’s cramp: a double-blind study. Neurology 1993, 43:183–185.

    PubMed  CAS  Google Scholar 

  28. Bluthner M, Haugke C, Kalischewski P: The treatment of lateral epicondylitis elbow with botulinum toxin A: a first experience. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R14.

    Google Scholar 

  29. Placzek R, Meiss L: Temporary chemical denervation with botulinum toxin A in epicondylitis radialis: a therapy trial in 14 patients. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R34.

    Google Scholar 

  30. Kehl LJ, Trempe TM, Hargreaves KM: A new animal model for assessing mechanisms and management of muscle hyperalgesia. Pain 2000, 85:333–343.

    Article  PubMed  CAS  Google Scholar 

  31. Thunberg J, Ljubisavljevic M, Djupsjobacka M, Johansson H: Effects on the fusimotor-muscle spindle system induced by intramuscular injections of hypertonic saline. Exp Brain Res 2002, 142:319–326.

    Article  PubMed  Google Scholar 

  32. Graven-Nielsen T, Mense S: The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain 2001, 17:2–10. An excellent review of the pathophysiologic mechanisms of acute and chronic muscle pain.

    Article  PubMed  CAS  Google Scholar 

  33. Jensen TS: Recent advances in pain research: implications for chronic headache. Cephalalgia 2001, 21:765–769.

    Article  PubMed  CAS  Google Scholar 

  34. Barlas P, Walsh DM, Baxter GD, Allen JM: Delayed onset muscle soreness: effect of an ischemic block on mechanical allodynia in humans. Pain 2000, 87:221–225.

    Article  PubMed  CAS  Google Scholar 

  35. Bennett GJ: Update on the neurophysiology of pain transmission and modulation: focus on the NMDA-receptor. J Pain Symptom Manage 2000, 19(suppl 1):S2-S6.

    Article  PubMed  CAS  Google Scholar 

  36. Mense S: Pathophysiology of low back pain and the transition to the chronic state: experimental data and new concepts. Schmerz 2001, 15:413–417.

    Article  PubMed  CAS  Google Scholar 

  37. Zhang L, Hoff AO, Wimalawansa SJ, et al.: Arthritic calcitonin/ alpha calcitonin gene-related peptide knockout mice have reduced nociceptive hypersensitivity. Pain 2001, 89:265–273.

    Article  PubMed  CAS  Google Scholar 

  38. Jensen R: Pathophysiologic mechanisms of tension-type headache: a review of epidemiologic and experimental studies. Cephalalgia 1999, 19:602–621.

    Article  PubMed  CAS  Google Scholar 

  39. Svensson P, Graven-Nielsen T, Matre D, Arendt-Nielsen L: Experimental muscle pain does not cause long-lasting increases in resting electromyographic activity. Muscle Nerve 1998, 21:1382–1389.

    Article  PubMed  CAS  Google Scholar 

  40. Cui M, Aoki R: Botulinum toxin A (BTX-a) reduces inflammatory pain in the rat formalin model. Cephalalgia 2000, 20:414–0.

    Article  Google Scholar 

  41. Schulte-Matler WJ, Blersch W, Przywara S, et al.: Botulinum toxin A and the cutaneous nociception in humans. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R39.

    Google Scholar 

  42. McRoberts JA, Coutinho SV, Marvizon JC, et al.: Role of peripheral N-methyl-D-aspartate (NMDA) receptors in visceral nociception in rats. Gastroenterology 2001, 120:1737–1748.

    Article  PubMed  CAS  Google Scholar 

  43. De Stefano R, Selvi E, Villanova M, et al.: Image analysis quantification of substance P immunoreactivity in the trapezius muscle of patients with fibromyalgia and myofascial pain syndrome. J Rheumatol 2000, 27:2906–2910.

    PubMed  Google Scholar 

  44. Cui M, Li Z, You S, Khanijou S, Aoki R: Mechanisms of the antinociceptive effect of subcutaneous Botox": inhibition of peripheral and central nociceptive processing. Abstracts of the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Arch Pharmacol 2002, 365:R17. Another important finding in the search for the mechanism of the analgesic action of botulinum toxin type A. Peripheral glutamate levels were reduced and central sensitization was prevented as a result.

    Article  CAS  Google Scholar 

  45. Ishikawa H, Mitsui Y, Yoshitomi T, et al.: Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Jpn J Ophthalmol 2000, 44:106–109.

    Article  PubMed  CAS  Google Scholar 

  46. Morris JL, Jobling P, Gibbins IL: Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. Am J Physiol Heart Circ Physiol 2001, 281:2124–2132.

    Google Scholar 

  47. Knutson GA: The role of the gamma-motor system in increasing muscle tone and muscle pain syndromes: a review of the Johansson/Sojka hypothesis. J Manipulative Physiol Ther 2000, 23:564–572.

    Article  PubMed  CAS  Google Scholar 

  48. Filippi GM, Errico P, Santarelli R, et al.: Botulinum A toxin effects on rat jaw muscle spindles. Acta Otolaryngol 1993, 113:400–404.

    PubMed  CAS  Google Scholar 

  49. Rosales RL, Arimura K, Takenaga S, Osame M: Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle Nerve 1996, 19:488–496.

    Article  PubMed  CAS  Google Scholar 

  50. Wiegand H, Erdmann G, Wellhoner HH: 125I-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn Schmiedebergs Arch Pharmacol 1976, 292:161–165.

    Article  PubMed  CAS  Google Scholar 

  51. Aoki R: The development of Botox: its history and pharmacology. Pain Digest 1998, 8:337–341.

    Google Scholar 

  52. Purkiss J, Welch M, Doward S, Foster K: Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurone: involvement of two distinct mechanisms. Biochem Pharmacol 2000, 59:1403–1406.

    Article  PubMed  CAS  Google Scholar 

  53. Cuesta MC, Arcaya JL, Cano G, et al.: Opposite modulation of capsaicin-evoked substance P release by glutamate receptors. Neurochem Int 1999, 35:471–478.

    Article  PubMed  CAS  Google Scholar 

  54. Urban MO, Gebhart GF: Central mechanisms in pain. Med Clin North Am 1999, 83:585–596.

    Article  PubMed  CAS  Google Scholar 

  55. McMahon HT, Foran P, Dolly JO, et al.: Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gammaaminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. J Biol Chem 1992, 267:21338–21343.

    PubMed  CAS  Google Scholar 

  56. Jung HH, Lauterburg T, Burgunder JM: Expression of neurotransmitter genes in rat spinal motoneurons after chemodenervation with botulinum toxin. Neuroscience 1997, 78:469–479.

    Article  PubMed  CAS  Google Scholar 

  57. Humm AM, Pabst C, Lauterburg T, Burgunder JM: Enkephalin and aFGF are differentially regulated in rat spinal motoneurons after chemodenervation with botulinum toxin. Exp Neurol 2000, 161:361–372.

    Article  PubMed  CAS  Google Scholar 

  58. Heinricher MM, McGaraughty S, Tortorici V: Circuitry underlying antiopioid actions of cholecystokinin within the rostral ventromedial medulla. J Neurophysiol 2001, 85:280–286.

    PubMed  CAS  Google Scholar 

  59. Wu HE, Hung KC, Mizoguchi H, et al.: Roles of endogenous opioid peptides in modulation of nocifensive response to formalin. J Pharmacol Exp Ther 2002, 300:647–654.

    Article  PubMed  CAS  Google Scholar 

  60. Mulderry PK, Ghatel MA, Spokes RA, et al.: Differential expression of alpha-CGRP and beta-CGRP by primary sensory neurons and enteric autonomic neurons of the rat. Neuroscience 1988, 25:195–205.

    Article  PubMed  CAS  Google Scholar 

  61. Duggan MJ, Quinn CP, Chaddock JA, et al.: Inhibition of release of neurotransmitters from rat dorsal root ganglia by a novel conjugate of a Clostridium botulinum toxin A endopeptidase fragment and Erythrina cristagalli lectin. J Biol Chem 2002, in press.

Download references

Author information

Authors and Affiliations

  1. EMG and Neuromuscular Service, University of California, San Diego, West Arbor Drive, 92103-8465, San Diego, CA, USA

    Geoffrey Sheean MD

Authors
  1. Geoffrey Sheean MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sheean, G. Botulinum toxin for the treatment of musculoskeletal pain and spasm. Current Science Inc 6, 460–469 (2002). https://doi.org/10.1007/s11916-002-0065-y

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11916-002-0065-y

Keywords

Search

Navigation